|
Accueil > Actualité
Bristol Myers: positive 5-year results for Sotyktu
(CercleFinance.com) - Bristol Myers Squibb reports further positive 5-year results from the POETYK PSO long-term extension trial (LTE) of Sotyktu (deucravacitinib) in adults with moderate-to-severe plaque psoriasis.
The pharmaceutical company notes that the safety profile of Sotyktu has remained consistent over five years, with over 5,000 patient-years of exposure in the trial, with no new safety signals identified. It adds that in continuously treated patients, clinical response rates were maintained from year 1 to year 5, including Psoriasis Area and Severity Indexes (PASI) 75 and 90, as well as Static Physician Global Assessment (sPGA) 0/1. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
21/02/2025 17:32
ADPpoursuit son repli, l'avis d'un analyste 21/02/2025 17:06 Rolls-Roycecontrat d'achat d'électricité avec SWU 21/02/2025 16:41 Airbusle satellite 'Biomass' de l'ESA en route pour Kourou 21/02/2025 16:30 KKRinvestit dans un complexe de logements à Stockholm 21/02/2025 15:45 Engiela Commission européenne approuve une aide d'Etat 21/02/2025 15:35 Repsolplombé par une dégradation de broker Tous les articles sociétés |
